Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.

Medicine - 31 Jul 2026

Guo Xiaoyan, Liu Likai, Yu Hongyan, Zhao Shifeng, Wang Chunyan, Wang Xiansheng

Abstract excerpt

This single-center retrospective cohort study investigated baseline clinical, molecular, and treatment-related factors associated with early progression among patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors (EGFR-TKIs) between June 2022 and June 2025. Eligible patients treated during the study period were consecutively screened...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to ErbB Receptors

Share to TP53 gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42536589
DOI: 10.1097/MD.0000000000049948
PMCID: PMC13433059

Genes

EGFR
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study.PMID 42536589Read ↗

Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.Semantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer.Semantic proximity Read ↗

EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022.Semantic proximity Read ↗

Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).Semantic proximity Read ↗

Aggressive Progression to EGFR Tyrosine Kinase inhibitors in Advanced NSCLC Patients: Concomitant Mutations, Prognostic Indicator and Subsequent ManagementSemantic proximity Read ↗

Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.Semantic proximity Read ↗

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read ↗

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity Read ↗

The BREATHE project: An observational prospective cohort integrating clinical data, blood samples and tumor tissue from newly diagnosed patients with lung cancerSemantic proximity Read ↗

Evidence from resected early-stage non-small cell lung cancer with EGFR mutation: a literature review.Semantic proximity Read ↗

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.